Cargando…

COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19

Evaluation of the safety and immunogenicity of new vaccine platforms is needed to increase public acceptance of coronavirus disease 2019 (COVID-19) vaccines. Here, we evaluated the association between reactogenicity and immunogenicity in healthy adults following vaccination by analyzing blood sample...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heo, Jung Yeon, Seo, Yu Bin, Kim, Eun Jin, Lee, Jacob, Kim, Young Rong, Yoon, Jin Gu, Noh, Ji Yun, Cheong, Hee Jin, Kim, Woo Joo, Yoon, Soo-Young, Choi, Ju-Yeon, Lee, Young Jae, Lee, Hye Won, Kim, Sung Soon, Kim, Byoungguk, Song, Joon Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480614/ https://www.ncbi.nlm.nih.gov/pubmed/36119092 http://dx.doi.org/10.3389/fimmu.2022.975363

Ejemplares similares

Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination
por: Hyun, Hakjun, et al.
Publicado: (2021)

Correlation between Reactogenicity and Immunogenicity after the ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccination
por: Lim, So Yun, et al.
Publicado: (2021)

Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations
por: Lee, Tae Hwan, et al.
Publicado: (2023)

Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines
por: Kim, Ji Yeun, et al.
Publicado: (2021)

Antibody Response Induced by Two Doses of ChAdOx1 nCoV-19, mRNA-1273, or BNT162b2 in Liver Transplant Recipients
por: Lim, So Yun, et al.
Publicado: (2022)

Stevens-Johnson Syndrome Following ChAdOx1 nCoV-19 Vaccination (AstraZeneca)
por: Lee, Hyo Jin, et al.
Publicado: (2023)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
por: Kim, Jinnam, et al.
Publicado: (2023)

Immunogenicity and Durability of Antibody Responses to Homologous and Heterologous Vaccinations with BNT162b2 and ChAdOx1 Vaccines for COVID-19
por: Kim, Dong-In, et al.
Publicado: (2022)

Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea
por: Bae, Seongman, et al.
Publicado: (2021)

Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine
por: Kang, Yu Min, et al.
Publicado: (2021)

Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
por: Tenbusch, Matthias, et al.
Publicado: (2021)

Reactogenicity and Immunogenicity of the ChAdOx1 nCOV-19 Coronavirus Disease 2019 Vaccine in South Korean Healthcare Workers
por: Hyun, JongHoon, et al.
Publicado: (2022)

A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination
por: Kim, Seok Hyun, et al.
Publicado: (2022)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19
por: Richardson, Christopher D
Publicado: (2021)

Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies
por: Radhwi, Osman O., et al.
Publicado: (2022)

BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes
por: Abdul-Jawad, Sultan, et al.
Publicado: (2022)

Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
por: Wei, Jie, et al.
Publicado: (2023)

Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity
por: Bae, Seongman, et al.
Publicado: (2022)

Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea
por: Jeon, Minji, et al.
Publicado: (2021)

Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience
por: Kim, Si-Ho, et al.
Publicado: (2021)

Comprehensive assessment of SARS-CoV-2 antibodies against various antigenic epitopes after naive COVID-19 infection and vaccination (BNT162b2 or ChAdOx1 nCoV-19)
por: Lee, Jihyun, et al.
Publicado: (2022)

A Case Report of Thrombotic Thrombocytopenia After ChAdOx1 nCov-19 Vaccination and Heparin Use During Hemodialysis
por: Son, Young-Bin, et al.
Publicado: (2022)

Effect of short-term corticosteroid use on reactogenicity and immunogenicity of the first dose of ChAdOx1 nCoV-19 vaccine
por: Yang, Jinyoung, et al.
Publicado: (2021)

Effects of Short-Term Corticosteroid Use on Reactogenicity and Immunogenicity of the First Dose of ChAdOx1 nCoV-19 Vaccine
por: Yang, Jinyoung, et al.
Publicado: (2021)

Breakthrough infections and waning immune responses with ChAdOx1 nCoV‐19 or mRNA vaccine in healthcare workers
por: Lim, So Yun, et al.
Publicado: (2022)

Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19—BNT162b2 mRNA Vaccination
por: Catry, Emilie, et al.
Publicado: (2022)

BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant
por: Sheikh, Aziz, et al.
Publicado: (2021)

Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine
por: Lim, Sung-Hee, et al.
Publicado: (2021)

Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis
por: Kim, Dae Kyu, et al.
Publicado: (2022)

Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
por: Agrati, Chiara, et al.
Publicado: (2021)

Immunogenicity of Third-dose BNT162b2 mRNA Vaccine Following Two Doses of ChAdOx1 in Health Care Workers: A Prospective Longitudinal Study
por: Kim, Jung-Ah, et al.
Publicado: (2022)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022)

A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
por: Kim, Gyungah, et al.
Publicado: (2021)

Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes
por: Hu, Yuxuan, et al.
Publicado: (2023)

Anti-SARS-CoV-2 Neutralizing Antibody Responses after Two Doses of ChAdOx1 nCoV-19 vaccine (AZD1222) in Healthcare Workers
por: Lim, Sera, et al.
Publicado: (2022)

Safety and immunogenicity of intradermal administration of fractional dose CoronaVac(®), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
por: Chatsiricharoenkul, Somruedee, et al.
Publicado: (2022)

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
por: Behrens, Georg M. N., et al.
Publicado: (2022)

Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine
por: Huh, Kyungmin, et al.
Publicado: (2021)

Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_007r409dhje0c1obgg6bquco7p